EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers

Trial Profile

EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms ESPAC-4
  • Most Recent Events

    • 07 Jun 2016 Results assessing survival presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 04 Dec 2015 Accrual to date is 64% according to United Kingdom Clinical Research Network.
    • 03 Jun 2015 Accrual to date is 63% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top